284 related articles for article (PubMed ID: 37450935)
21. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
22. Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni H; Soe Z; Moe S
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126
[TBL] [Abstract][Full Text] [Related]
23. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
[TBL] [Abstract][Full Text] [Related]
24. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
25. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
[TBL] [Abstract][Full Text] [Related]
26. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.
Howcroft M; Walters EH; Wood-Baker R; Walters JA
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD005074. PubMed ID: 27990628
[TBL] [Abstract][Full Text] [Related]
27. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
Rabe KF; Celli BR; Wechsler ME; Abdulai RM; Luo X; Boomsma MM; Staudinger H; Horowitz JE; Baras A; Ferreira MA; Ruddy MK; Nivens MC; Amin N; Weinreich DM; Yancopoulos GD; Goulaouic H
Lancet Respir Med; 2021 Nov; 9(11):1288-1298. PubMed ID: 34302758
[TBL] [Abstract][Full Text] [Related]
29. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.
Daniels JM; Snijders D; de Graaff CS; Vlaspolder F; Jansen HM; Boersma WG
Am J Respir Crit Care Med; 2010 Jan; 181(2):150-7. PubMed ID: 19875685
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP; Rabe KF; Hanania NA; Vogelmeier CF; Cole J; Bafadhel M; Christenson SA; Papi A; Singh D; Laws E; Mannent LP; Patel N; Staudinger HW; Yancopoulos GD; Mortensen ER; Akinlade B; Maloney J; Lu X; Bauer D; Bansal A; Robinson LB; Abdulai RM;
N Engl J Med; 2023 Jul; 389(3):205-214. PubMed ID: 37272521
[TBL] [Abstract][Full Text] [Related]
31. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
32. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction.
Martinez FJ; Vestbo J; Anderson JA; Brook RD; Celli BR; Cowans NJ; Crim C; Dransfield M; Kilbride S; Yates J; Newby DE; Niewoehner D; Calverley PM;
Am J Respir Crit Care Med; 2017 Apr; 195(7):881-888. PubMed ID: 27767328
[TBL] [Abstract][Full Text] [Related]
33. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
[TBL] [Abstract][Full Text] [Related]
34. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
[TBL] [Abstract][Full Text] [Related]
35. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.
Lenferink A; Brusse-Keizer M; van der Valk PD; Frith PA; Zwerink M; Monninkhof EM; van der Palen J; Effing TW
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011682. PubMed ID: 28777450
[TBL] [Abstract][Full Text] [Related]
36. Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.
Martinez FJ; Rabe KF; Calverley PMA; Fabbri LM; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VKT; Siddiqui S; Reisner C; Zetterstrand S; Román J; Purkayastha D; Bagul N; Rennard SI
Am J Respir Crit Care Med; 2018 Nov; 198(10):1268-1278. PubMed ID: 29763572
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial.
Wise RA; Chapman KR; Scirica BM; Daoud SZ; Lythgoe D; Garcia-Gil E
Int J Chron Obstruct Pulmon Dis; 2021; 16():689-699. PubMed ID: 33776428
[TBL] [Abstract][Full Text] [Related]
38. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.
Singh D; Wedzicha JA; Siddiqui S; de la Hoz A; Xue W; Magnussen H; Miravitlles M; Chalmers JD; Calverley PMA
Respir Res; 2020 Sep; 21(1):240. PubMed ID: 32943047
[TBL] [Abstract][Full Text] [Related]
39. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials.
Bafadhel M; Peterson S; De Blas MA; Calverley PM; Rennard SI; Richter K; Fagerås M
Lancet Respir Med; 2018 Feb; 6(2):117-126. PubMed ID: 29331313
[TBL] [Abstract][Full Text] [Related]
40. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
Yang IA; Clarke MS; Sim EH; Fong KM
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD002991. PubMed ID: 22786484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
